Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 11/20 | 0.40 |
| ▸ | BRD4 | O60885 | 8/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | EP300 | Q09472 | 3/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 2/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24437321 | 0.98 | GRM5 (0.40) | CREBBPBRD4KDM4CEP300THRB | |
| SCHEMBL24437166 | 0.95 | OPRM1 (0.40) | CREBBPBRD4KDM4CEP300THRB | |
| SCHEMBL24437333 | 0.89 | WNT1 (0.39) | CREBBPBRD4KDM4CEP300OPRM1 | |
| SCHEMBL24437314 | 0.84 | KDM4C (0.40) | CREBBPBRD4KDM4CGRM5OPRM1 | |
| SCHEMBL24437130 | 0.80 | CNR1 (0.50) | KDM4C | |
| SCHEMBL24437128 | 0.78 | CNR1 (0.53) | KDM4COPRM1OPRL1 | |
| SCHEMBL24437152 | 0.74 | NPC1 (0.44) | KDM4COPRM1OPRL1GAAGSK3A | |
| SCHEMBL24437308 | 0.69 | KDM4C (0.57) | KDM4C | |
| SCHEMBL29601258 | 0.69 | KDM4C (0.57) | KDM4C | |
| SCHEMBL24437163 | 0.67 | CNR1 (0.51) | THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459938-B2 | ORAI channel inhibitors | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20220153735-A1 | Orai Channel Inhibitors | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2022-05-19 | — | — | US | disclosed |
| US-20220153735-A1 | Orai Channel Inhibitors | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459938-B2 | ORAI channel inhibitors | ORAI1, CACNA1E, ORAI3 | CREBBP 1995/4885BRD4 1522/4885KDM4C 2563/4885 |
| US-20220153735-A1 | Orai Channel Inhibitors | ORAI2, ORAI1, ORAI3 | CREBBP 1680/4885BRD4 2534/4885KDM4C 3959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.